Gut bacteria may be doing more than shaping digestion. In a new laboratory-based study, bacteria-linked sugars in the gut emerged as a possible hidden contributor to two devastating neurodegenerative diseases: amyotrophic lateral sclerosis and frontotemporal dementia. The work does not prove cause and effect in people, but it does sharpen a question that has long remained unresolved: why do some people with a genetic risk develop disease while others do not? The answer may involve an inflammatory chain reaction that begins far from the brain and ends inside it.
Why this matters right now for ALS and FTD
ALS and FTD are closely linked conditions that can overlap, and both involve neuron death. ALS affects muscle movement and is eventually fatal, while FTD brings major changes in behavior and language and can also affect movement. The study focuses on a variation of the C9ORF72 gene, which can cause both conditions, but does not affect everyone who carries it. That gap is what made the new findings important: the research team wanted to identify other triggers that might help explain disease onset and progression. In this context, bacteria became the central suspect.
Using a mouse model, researchers found a specific type of glycogen produced by gut bacteria. The sugar appears to trigger brain inflammation and neuron death. Aaron Burberry, assistant professor of pathology at Case Western Reserve University, said: “We found that harmful gut bacteria produce inflammatory forms of glycogen – a type of sugar – and that these bacterial sugars trigger immune responses that damage the brain. ” He added that this opens the door to developing treatments that target the process.
What the laboratory evidence showed
The study was methodical. Researchers engineered mice without the C9ORF72 gene to mimic the variant seen in people, then tested different mixes of gut bacteria to see how immune systems responded. That work led them to glycogen production and then to Parabacteroides merdae, one strain that creates it. When this bacteria was introduced to mice bred without gut bacteria, it caused serious inflammation and a breakdown of the blood-brain barrier.
Human stool samples added another layer. Higher-than-normal levels of inflammatory glycogen were found in 15 out of 22 ALS patients and in one FTD patient, compared with four out of 12 healthy controls. The research also suggests that the protein encoded by C9ORF72 acts as a brake on glycogen, helping explain why the gene variation matters. In the researchers’ published paper, they wrote that microbes that accumulate inflammatory glycogen are enriched in the gut of ALS patients, and that microbial glycogen may be one of many environmental and lifestyle factors interacting with predisposed genes.
The gut-brain link may be more actionable than expected
One of the most notable results came when affected mice were given alpha-amylase, an enzyme that breaks down glycogen. In those animals, inflammation levels dropped and lifespans were extended, even though motor performance did not improve. That distinction matters. It suggests that reducing the inflammatory signal may alter disease pressure without immediately reversing established damage. It also points toward a possible future strategy focused on the gut rather than the brain.
That is still early-stage science, and the study itself does not claim a ready-made treatment. But it does strengthen the idea that bacteria may influence disease risk through immune pathways rather than through a single direct mechanism.
Expert perspective and broader impact
Steven Flavell, associate professor in MIT’s Brain and Cognitive Sciences Department and an investigator of the Howard Hughes Medical Institute, said the broader field has reached a point where the links are no longer the only focus. “It’s been clear that there are links for some time. Our study aimed to identify the hard mechanisms of how a host nervous system is affected by bacteria in the alimentary canal, ” he said. He added that understanding those mechanisms could help improve attempts to intervene with therapeutic drugs or supplements.
For now, the regional and global significance lies in what the study adds to the bigger picture of neurodegenerative disease. It suggests that gut biology may help explain why a genetic vulnerability becomes active in some people and not in others. That matters not only for ALS and FTD, but for the wider search for disease triggers that sit outside the brain. If inflammatory bacteria can shape risk through the gut, how many other neurological diseases may have hidden biological beginnings in the body before they ever appear in the mind?
